Coartem (Artemether and Lumefantrine) Market Size, Share, Growth, and Industry Analysis, By Type (Artemether and Lumefantrine), By Application (Hospital Pharmacy, Retail Pharmacy and Online Pharmacy), and Regional Forecast to 2033

COARTEM (ARTEMETHER AND LUMEFANTRINE) MARKET OVERVIEW

The global Coartem (Artemether and Lumefantrine) market is estimated to be valued at USD 47.93 billion in 2024, with expectations to reach approximately USD 69.71 billion by 2033, reflecting a compound annual growth rate (CAGR) of 4.25% during the forecast period.

There is an important part of the global market for antimalarial drugs, which is that of Coartem (artemether and lumefantrine), among others, which rely for their success on the ability to treat the strain of Plasmodium from which was derived the name P. falciparum malaria, plus being a fixed-dose combination therapy in addition to the other benefits that have made it popular in malaria-endemic regions. Malaria prevalence and government efforts to combat its effects, as well as agencies like WHO, will drive the market's dynamics. In addition, challenges such as drug resistance and limited access to the drug in quite a number of rural areas would further shape the emerging market.

COVID-19 IMPACT

Market growth was hindered by COVID-19, affecting antimalarial availability and access

The global COVID-19 pandemic has been unprecedented and staggering, with the market experiencing lower-than-anticipated demand across all regions compared to pre-pandemic levels. The sudden market growth reflected by the rise in CAGR is attributable to the market’s growth and demand returning to pre-pandemic levels.

So it seems like a very newly grown market caused by a tremendous recession, as in the case with many other antimalarials, caused by the COVID-19 pandemic. Disruptions of global supply chains and transport affected the production and distribution of antimalarial medicines. This has led to a very reduced availability of these medicines in many malaria-endemic countries. Meanwhile, the health system was getting overwhelmed with the disease because of diverting munificent health services out of the treatment sphere, which further limited access to treatment. Costs and travel restrictions created by lockdowns compounded by economic adversities impacted negatively on the outreach affordability of patients, leading to the performance of the market being significantly denoted in the negative manner.

LATEST TREND

"Market growth in Coartem includes pediatric formulations, partnerships, and innovations"

Some of the growing trends in the Coartem (Artemether and Lumefantrine) market include a higher adoption of combination therapies, renewed focus in public-private partnerships, and improvement in drug delivery systems. Most strikingly, developing dispersible tablet formulations for children stands for improvement in access and compliance in the pediatric population. These formulations specifically meet a major unmet need of malaria treatment in the regions where there are very high rates of child mortality due to the disease. The development of such pediatric formulations receives great support from governments and organizations in their campaigns for innovative solutions toward malaria elimination. This indicates a dramatic shift towards addressing specific needs within the market.

COARTEM (ARTEMETHER AND LUMEFANTRINE) MARKET SEGMENTATION

BY TYPE

Based on Type, the global market can be categorized into Artemether and Lumefantrine

• Artemether: Artemether is one of the two ingredients of Coartem, extremely fast-acting against Plasmodium falciparum; it interferes in the metabolic processes of the parasite and gives fast relief in malaria symptoms. The market driven by Artemether is that which combines it in fixed-dose therapies or areas with increasing malaria endemicity. Alone, Artemether is not a widely used agent because drug resistance prevention requires combinations for therapy.

• Lumefantrine: Lumefantrine is combined with artemether in Coartem by providing sustained antimalarial activity. Ensure complete clearance of the parasite and reduce any risk of relapse, thus improving efficacy. Growing demand for Lumefantrine is mainly due to it being a key component of combination therapy and a global focus on malaria eradication. It is challenging in resource-scarce settings where it is found, underlining the need for better distribution networks.

BY APPLICATION

Based on application, the global market can be categorized into Hospital Pharmacy, Retail Pharmacy and Online Pharmacy

• Hospital Pharmacy: Hospital pharmacies are crucial centers in the distribution of Coartem and immediate accessibility to patients receiving treatment for malaria. Such pharmacies have the ability to dispense great quantities of Coartem, and in many instances of high malaria incidence percentage, these facilities would be the first source for its procurement. There is a preponderance of their availability due to the presence of professional service and the rapidity of response to serious situations. Unfortunately, there have been deficiencies because of supply issues and logistical challenges affecting the availability of Coartem in some scarce and poorly funded hospitals.

• Retail Pharmacy: Coartem is distributed through another set of channels into retail pharmacies. Visit an individual customer in an urban or rural town using street pharmacy. The person usually defines the over-the-counter application because they cannot visit the pharmacy even if they have a prescription for it. This is one quickly developing segment buoyed by the rising incidence and awareness of combined antimalarial therapy. But access is also limited in poor areas by poor stock and affordability.

• Online Pharmacy: Online pharmacies are yet another emerging category that will define the Coartem space in terms of convenience and accessibility through digital pathways. They target those consumers who prefer the medication without necessarily going into physical markets, especially within urban settings. The COVID-19 pandemic just hastened the move toward online pharmacies and ill-necessitated access-denied measures. But such channels still face a big challenge vis-à-vis counterfeit drugs and regulatory disadvantages.

MARKET DYNAMICS

Market dynamics include driving and restraining factors, opportunities and challenges stating the market conditions.

DRIVING FACTOR

"Disease Invasion in a Malaria Hatching Region"

An increasing incidence of malaria in endemic regions like sub-Saharan Africa and Southeast Asia is an important factor propelling the market for Coartem. The primary cause of severe cases of malaria is Plasmodium falciparum, which is now pushing the demand for good combination therapy such as Coartem. National governments and global health organizations like the WHO have scaled up their efforts to fight malaria, thus contributing to market expansion. Also, effective clinical evidence and the mortality effect produced by the Coartem product as well increase its demand in high-incidence areas. As climate change expands malaria-susceptible regions, the need for strong solutions to treatment will increase. The rising incidence of malaria altogether justifies it as an important avenue for expansion in the market.

"Supportive Government and Organizational Initiatives"

Available within the scope of such governmental initiatives and international support schemes, one may view the impetus to the Coartem market as much due to the subsidies, funding, and distribution programs that are targeted for delivering supplies of Coartem in resource-challenged settings under the auspices of organizations like the Global Fund and WHO. Campaigns to increase early diagnosis and treatment have sparked increased need for antimalarials, including Coartem. Continued focus on helping build public-private partnerships will go a long way in strengthening supply chains and helping to guarantee reliable availability even in difficult locations. All efforts continued to be directed towards achieving the global eradication of malaria, and investments have therefore rightly increased into proven effective treatments such as Coartem. The cumulative effect of such initiatives continues to spur the growth of this market by narrowing affordability and access barriers.

RESTRAINING FACTOR

"Drug resistance to Coartem hampers malaria treatment, slowing market growth"

The barreling-up threat of resistance to drugs is the major constraint in the Coartem (Artemether and Lumefantrine) Market Growth. Resistance to artemisinin-based drugs such as Coartem has already been noted in regions, mostly in Southeast Asia. As this decreases the efficacy of treatment, it makes malaria control much more difficult and stimulates the need for other therapies. Drug resistance also increases the financial burden on health systems, requiring more complicated treatment regimens. This requires continuous research and surveillance, further slowing market growth.

OPPORTUNITY

"Pediatric formulations in Coartem drive market growth by improving accessibility"

The pediatric formulation, such as dispersible tablets, represents a significant growth opportunity in the Coartem market. These formulations improve accessibility and treatment adherence in children, who constitute a vulnerable population for malaria in endemic regions. There is increasing awareness and demand for malaria treatments for children; hence, the more that pediatric options are available, the better for market growth. Further, focus is being shared by governments and global health organizations on malaria treatment for children. In fact, this encourages such an opportunity for this development. This also goes with the global mission to reduce child mortality due to malaria.

CHALLENGE

"Limited access, infrastructure, and economic factors hinder Coartem market growth"

Limited access to Coartem among rural and remote areas with a high burden of malaria is among the major challenges to the Coartem market. Poor infrastructural settings, transportation barriers, and inadequate health care facilities affect the distribution of Coartem. Treatment delays will ultimately lead to a case of severe malaria resulting in increased mortality. Furthermore, the dearth of trained health professionals presents another challenge for diagnosis and proper administration of the drug. Economic factors prevent most from affording treatment. Access, therefore, is one of the critical issues in expanding the market.

COARTEM (ARTEMETHER AND LUMEFANTRINE) MARKET REGIONAL INSIGHTS

To Know Key Insights of the Market

Request Free Sample

• NORTH AMERICA

North America's Coartem market growth is driven by global health initiatives

The market for Coartem comprises Artemether and Lumefantrine that is primarily being dominated by North America due to the strong healthcare infrastructure and high R&D investments, as well as efficient pharmaceutical distribution networks. However, such a market is flourishing under the lifting of philanthropic initiatives, research efforts, and global health programs targeting malaria control in endemic areas even though malaria is not endemic in the region. This role is played by the United States Coartem (Artemether and Lumefantrine) Market as a major funder of malaria eradication efforts through agencies like USAID and the Centers for Disease Control and Prevention; thus, the market for Coartem activities is greatly strengthened by these initiatives. Global health organization collaborations also support such an emerging market. Such parameters are what contribute to North America's dominance in the Coartem market.

• EUROPE

European investments, research, and advocacy drive Coartem market growth globally

Major inputs from Europe in the Coartem (Artemether and Lumefantrine) Market Share basket comprise hefty investments in global malaria control programs and research. The contributions of hurried European countries, such as the United Kingdom, France, and Germany, are in funding major initiatives of global proportions, such as the Global Fund and the World Health Organization's Fund for malaria treatment and prevention in endemic areas across the continent. Europe's pharmaceutical industry, including its manufacturing giants, also guarantees supply and access to Coartem. European organizations are actively conducting research and/or clinical trials on new formulations. Their advocacy for the eradication of malaria makes them even more relevant concerning the claims they can make on the Coartem market. These contributions further improve the worldwide access and outreach of the market.

• ASIA

Asia's market growth in Coartem is driven by malaria burden and collaboration

Asia has a very high contribution to the Coartem, or Artemether and Lumefantrine, market in the world because of its very high malaria burden, especially in Southeast Asia. The way this region uses the specialty drug on a national basis in its malaria treatment regimes is much more pronounced. The high countries are India, Vietnam, and Indonesia, with heavy dependence on Coartem for effective malaria treatment. These local manufacturers in Asia also produce and distribute to ensure that the drug remains affordable and accessible. Further collaborative efforts with global health bodies help increase the region's weight on the market.

KEY INDUSTRY PLAYERS

"Novartis drives Coartem's market growth through innovation, partnerships, and donations"

The major players in the industry: Novartis, the key manufacturer of Coartem, have substantially penetrated the market with their distribution channels and continuous innovations. Coartem is manufactured by Novartis and other pharmaceutical companies in different formulations; for example, pediatric formulations are available for patients whose needs may not be similar to adults. Apart from this, they also partner with different agencies like WHO or USAID and let people access the drug in malaria-endemic areas through donations or lower-pricing strategies. Their research and awareness campaigns, along with their partnerships, go a long way in sustaining the market growth of Coartem, as well as contributing to global efforts toward malaria eradication.

LIST OF TOP COARTEM (ARTEMETHER AND LUMEFANTRINE) COMPANIES

• KPC Pharmaceuticals (CHINA)
• Kunming Pharmaceutical (CHINA)
• Kerui Nanhai Pharmaceutical (CHINA)
• Sanofi-Aventis (FRANCE)
• Guangxi Xiancaotang Pharmaceutical (CHINA)

KPC Pharmaceuticals is a key player in the production of artemisinin-based combination therapies (ACTs), contributing to approximately 30% of the global ACT supply. The company has significantly invested in large-scale cultivation of Artemisia annua, increasing artemisinin extraction efficiency by 25% over the past five years. Additionally, KPC Pharmaceuticals' recent partnerships with global health organizations have expanded its reach, resulting in a 40% increase in ACT distribution to malaria-endemic regions, improving accessibility to essential treatments.

Kunming Pharmaceutical, a major producer of antimalarial medications, has expanded its international market presence, contributing to over 35% of Artemether and Lumefantrine distribution in Asia and Africa. The company actively collaborates with government health agencies, ensuring a 30% increase in treatment accessibility across malaria-endemic regions. Additionally, investments in R&D have led to a 20% improvement in drug efficacy, enhancing treatment outcomes and resistance management. These advancements reinforce Kunming Pharmaceutical’s role in the global fight against malaria.

KEY INDUSTRY DEVELOPMENT

September 2023: A recent industrial development in the market for Coartem (Artemether and Lumefantrine) was that, in September 2023, Novartis launched a new dispersible tablet formulation specifically designed for pediatric patients. This development was aimed at improving treatment adherence in a younger age group by providing a convenient and easier-to-administer dosage form. The launch reflects Novartis's commitment to making malaria treatments accessible and to improving the effectiveness of eradication efforts all the more in areas where morbidity and mortality from malaria are greatest in children. This is part of their wider program that supports global malaria control initiatives.

REPORT COVERAGE

The study encompasses a comprehensive SWOT analysis and provides insights into future developments within the market. It examines various factors that contribute to the growth of the market, exploring a wide range of market categories and potential applications that may impact its trajectory in the coming years. The analysis takes into account both current trends and historical turning points, providing a holistic understanding of the market's components and identifying potential areas for growth.

This research report examines the segmentation of the market by using both quantitative and qualitative methods to provide a thorough analysis that also evaluates the influence of strategic and financial perspectives on the market. Additionally, the report's regional assessments consider the dominant supply and demand forces that impact market growth. The competitive landscape is detailed meticulously, including shares of significant market competitors. The report incorporates unconventional research techniques, methodologies and key strategies tailored for the anticipated frame of time. Overall, it offers valuable and comprehensive insights into the market dynamics professionally and understandably.